Citadel Advisors’s PLx Pharma Inc. Common Stock PLXP Stock Holding History

Citadel Advisors’s Portfolio PLXP Stock Details PLXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-38,998	Closed	-$57.5K	–	14040
2022 Q2	$95K	Sell	38,998 -2,164	-5%	-$6.01K	﹤0.01%	11469
2022 Q1	$167K	Sell	41,162 -28,904	-41%	-$158K	﹤0.01%	11737
2021 Q4	$562K	Buy	70,066 +4,793	+7%	+$56.2K	﹤0.01%	9408
2021 Q3	$1.26M	Buy	65,273 +22,973	+54%	+$401K	﹤0.01%	7542
2021 Q2	$584K	Buy	42,300 +27,887	+193%	+$330K	﹤0.01%	9701
2021 Q1	$131K	Buy	+14,413	New	+$105K	﹤0.01%	12197
2017 Q2	–	Sell	-1,913	Closed	-$20K	–	8250
2017 Q1	$20K	Buy	+1,913	New	+$20.8K	﹤0.01%	7246

Other funds holding PLXP

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

SGCA

Steel Grove Capital Advisors Memphis, Tennessee $949M AUM 23.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GSC

Ground Swell Capital Folly Beach, South Carolina $50.7M AUM 30.19% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UOTTAIMCU

University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Citadel Advisors's PLXP Position: Q3 2022 in Review

Citadel Advisors sold out of PLx Pharma Inc. Common Stock (PLXP) in Q3 2022, closing a stake of 38,998 shares — an estimated $57.5K sold.

Citadel Advisors first reported a position in PLXP in Q1 2017 and held it in 7 quarters. The position peaked at $1.26M in Q3 2021. 40 funds tracked by Wall St. Rank hold PLXP as of Q3 2022.

Citadel Advisors reported no remaining PLx Pharma Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Citadel Advisors sold 38,998 PLx Pharma Inc. Common Stock shares in Q3 2022, an estimated $57.5K.
Citadel Advisors first reported a position in PLx Pharma Inc. Common Stock in Q1 2017 and held it in 7 quarters.
Citadel Advisors's PLx Pharma Inc. Common Stock position peaked at $1.26M in Q3 2021.
40 funds tracked by Wall St. Rank held PLx Pharma Inc. Common Stock as of Q3 2022.

Based on Citadel Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.